Venture Capital · London (United Kingdom), St. Peter Port (Guernsey) · Founded 2012
Syncona is a FTSE250 company focused on founding, building, and funding healthcare companies. They aim to deliver transformational treatments for patients in areas of high unmet need, building a diversified portfolio of 20-25 globally leading life science businesses.
Series A, Series B, Series C
BioTech, Healthcare, Pharma
Autolus Therapeutics, Beacon Therapeutics, iOnctura, Spur Therapeutics, Quell Therapeutics, Anaveon, Resolution Therapeutics, Purespring Therapeutics, Forcefield Therapeutics, OMass Therapeutics, Mosaic Therapeutics, Kesmalea Therapeutics, Yellowstone Biosciences, Slingshot Therapeutics, Gyroscope Therapeutics, Blue Earth, Nightstar, Neogene Therapeutics, 14MG, Azeria Therapeutics, Clade Therapeutics